Crowdonomics
All companies

Novo Integrated Sciences, Inc.

Operating

Industrial & Manufacturing · Bellevue, WA

Estimated pre-money ⓘ
$466.0M
As of Apr 2020 · from Reg A Offering (2020) · our estimate: offering price × shares outstanding, not a stated valuation
Total raised
$0
Across 2 rounds since 2012
Latest share price
$2.00
Reg A Offering (2020) offering price

Financials

FY2001–FY2024 · from SEC filings · hover any figure for its source
$8.0M
−$738K
2017
$8.9M
−$2.1M
2018
$9.4M
−$392K
2019
$7.9M
−$4.9M
2020
$9.3M
−$4.5M
2021
$11.7M
−$32.8M
2022
$12.6M
−$13.2M
2023
$13.3M
−$16.2M
2024
RevenueNet income — beside revenue when positive, below the line when a loss

Chart shows the most recent 8 fiscal years; 16 earlier years are in the table below.

Metric
FY2001 audited
FY2002 audited
FY2003 audited
FY2004 audited
FY2005 audited
FY2006 audited
FY2007 audited
FY2008 audited
FY2009 audited
FY2010 audited
FY2011 audited
FY2012 audited
FY2013 audited
FY2014 audited
FY2015 audited
FY2016 audited
FY2017 audited
FY2018 audited
FY2019 audited
FY2020 audited
FY2021 audited
FY2022 audited
FY2023 audited
FY2024 audited
Income statement
Revenue
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
$7,178,246
$7,963,045
$8,894,464
$9,421,825
$7,860,567
$9,305,255
$11,737,937
$12,572,019
$13,294,357
Cost of goods sold
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
$4,670,615
$4,985,715
$5,471,376
$5,902,381
$4,802,195
$5,482,257
$6,938,699
$7,619,304
$7,551,853
Gross margin
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
35%
37%
38%
37%
39%
41%
41%
39%
43%
Net income
-$31,789
-$2,796,768
-$190,567
-$282,009
-$1,068,738
-$1,465,077
-$2,470,352
-$982,677
-$2,271,917
-$2,569,223
-$2,238,011
-$1,160,250
-$887,672
-$1,033,532
-$2,770,714
-$164,887
-$738,384
-$2,108,012
-$391,984
-$4,915,154
-$4,462,147
-$32,849,215
-$13,214,552
-$16,166,744
Taxes paid
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
-$111,702
—
—
—
—
-$22,302
—
—
Balance sheet
Cash
—
—
—
—
—
—
—
$2,857
$603,601
$128,264
$11,638
$6,293
$3,423
$1,831
$14,123
$54,350
$1,896,572
$675,705
$2,083,666
$2,067,718
$8,293,162
$2,178,687
$416,323
$844,584
Accounts receivable
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
$785,780
$1,128,898
$1,337,545
$1,463,529
$1,732,432
$1,468,429
$1,017,405
$1,467,028
$1,916,819
Total assets
—
—
—
—
—
—
—
—
—
$1,187,072
$25,812
$34,536
$357,719
$22,592
$27,873
$69,830
$5,514,390
$4,743,099
$32,273,369
$35,390,618
$61,958,281
$40,872,840
$35,563,047
$32,141,276
Short-term debt
—
—
—
—
—
—
—
—
—
$500
$500
$500
$375,136
$215,451
—
$147,517
$13,171
$382,350
—
—
—
—
—
—
Long-term debt
—
—
—
—
—
—
—
—
—
—
$2,212,834
$590,331
$747,839
$307,598
—
—
$427,522
—
$3,677,408
—
$9,619,253
$161,460
$342,443
$157,682
Total liabilities
—
—
—
—
—
—
—
—
—
$2,679,161
$2,353,923
$590,831
$1,122,975
$523,049
—
$9,979,917
$9,802,580
$4,570,329
$6,729,161
$5,818,988
$18,154,126
$18,825,269
$11,063,972
$17,527,351
Other
Headcount
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
33
—
—
—
—
—

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$466.0M
est. pre-money
Reg A+ · Equity · Apr 2020

Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.

Cap table

Share counts as of Aug 31, 2024
ClassOutstandingVotes / shareShare of totalLast price
Common stock19,054,523—100.0%—

Shares outstanding over timein today's share terms

19M9.5M0
Aug 2016May 2024
Common stockSplit / conversion

Changes in named holdersshares in today's terms · % of all shares at the time

Principal holders% as the filing states it, Dec 18, 2024

  • Sarfaraz Ali3,948 shares9.15%of company
  • Stockholders: ALMC-ASAP Holdings, Inc.1,290,858 shares6.54%of company
  • Christopher David485,695 shares2.46%of company

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Reg A+ · Equity · Apr 2020Closedvia DALMORE GROUP LLC
Raised $0 / $30MEst. pre-money $466M

Team

5 people
Robert Mattacchione
Chairman of the Board and Chief Executive Officer of Novo Integrated Sciences, Inc.
Christopher David
President and Director of Novo Integrated Sciences, Inc.
Pierre Dalcourt
Director of Novo Integrated Sciences, Inc. and President of Novo Healthnet Limited
Michael Gaynor
Secretary and Director of Novo Integrated Sciences, Inc.
Klara Radulyne
Principal Financial Officer of Novo Integrated Sciences, Inc.

Names and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.

  • Form 10-KDec 18, 20240001493152-24-050606
    EDGAR
  • Form 10-QJul 19, 20240001493152-24-028543
    EDGAR
  • Form 10-QApr 15, 20240001493152-24-014632
    EDGAR
  • Form 10-QJan 22, 20240001493152-24-003195
    EDGAR
  • Form 10-KDec 14, 20230001493152-23-044893
    EDGAR
  • Form 10-QJul 17, 20230001493152-23-024727
    EDGAR
  • Form 10-QMay 26, 20230001493152-23-019347
    EDGAR
  • Form 10-QMay 24, 20230001493152-23-018933
    EDGAR
Source: SEC EDGARCIK 0001138978NVShare price $2.00Last synced Aug 16, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.